MarketCapExport financials
Arrowhead Pharmaceuticals (ARWR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Arrowhead Pharmaceuticals Balance Sheet 2025-2003 | ARWR
Brief overview of Arrowhead Pharmaceuticals's balance sheet strength
The balance sheet is assessed across five available annual reports spanning 2015 to 2019.
Assets reached $349.8 million, compared with $132.3 million at the beginning. Growth of +164.5% and CAGR near 27.5% show active expansion.
Liability growth of +367.2% exceeded asset growth of +164.5%, increasing reliance on outside funding.
The equity ratio reached 69.9% from 83.3%. A high capital share reduces dependence on liabilities.
Cash exceeds interest-bearing debt, producing net debt of -$221.8 million. The balance sheet therefore carries a net cash position.
Cash accounts for 63.4% of assets versus 61.4% initially. The change indicates the degree of financial flexibility.
The balance sheet includes a negative accumulated result of -$419.3 million. It should be assessed alongside historical profits and capital distributions.
What the balance sheet shows
Arrowhead Pharmaceuticals retains a reasonably healthy balance sheet structure, which still needs support from earnings and cash flow.
Annual Balance Sheet Arrowhead Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-115 M | 14.7 M | 4.28 M | -26.4 M | -159 M | - | -222 M | -27.8 M | -22.3 M | -82.6 M | -80.5 M | -131 M | -18.1 M | -1.04 M | -6.9 M | - | - | - | - | - | - | - | - |
Long Term Debt |
104 M | 111 M | 105 M | 78.8 M | 23.3 M | - | - | 2.1 M | 2.33 M | 2.53 M | - | - | 50 K | 839 K | 607 K | - | - | - | - | - | - | - | - |
Long Term Debt Current |
7.29 M | 6.34 M | 10.6 M | 2.78 M | 2.25 M | 1.09 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
686 M | 846 M | 373 M | 135 M | 155 M | 20 M | 8.74 M | 4 M | 4.45 M | 7.51 M | 6.75 M | 4.98 M | 2.87 M | 2.39 M | 742 K | - | - | - | - | - | - | - | - |
Total Current Liabilities |
195 M | 103 M | 105 M | 139 M | 147 M | 40.7 M | 97.1 M | 12.4 M | 18.7 M | 25.6 M | 15.9 M | 11.8 M | 8.73 M | 5.33 M | 2.58 M | 4.28 M | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | 106 M | 16.4 M | 23.2 M | 33.2 M | 22.6 M | 16.8 M | 11.6 M | 7.72 M | 3.32 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
2.4 M | - | 866 K | 74.1 M | 111 M | 19.3 M | 77.8 M | 600 | 5.27 M | 2.57 M | 103 K | 103 K | 103 K | 37.5 K | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.63 B | -1.63 B | -1.03 B | -821 M | -645 M | -504 M | -419 M | -487 M | -433 M | -398 M | -317 M | -225 M | -166 M | -135 M | -114 M | -111 M | - | - | - | - | - | - | - |
Total Assets |
1.39 B | 1.14 B | 766 M | 692 M | 710 M | 523 M | 350 M | 112 M | 104 M | 128 M | 132 M | 183 M | 37.3 M | 16.5 M | 15.9 M | 12.4 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
227 M | 103 M | 111 M | 108 M | 184 M | 144 M | 222 M | 30.1 M | 24.8 M | 85.4 M | 81.2 M | 133 M | 19.1 M | 3.38 M | 7.51 M | 6.85 M | 2.02 M | - | - | - | - | - | - |
Book Value |
1.39 B | 1.14 B | 766 M | 692 M | 710 M | 523 M | 244 M | 95.2 M | 80.9 M | 95 M | 110 M | 166 M | 25.7 M | 8.81 M | 12.6 M | 12.4 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
466 M | 185 M | 271 M | 399 M | 409 M | 462 M | 245 M | 95.8 M | 81.4 M | 95.6 M | 110 M | 167 M | 27.5 M | 10 M | 12.8 M | 9.05 M | 4.86 M | 12.3 M | 26.5 M | 31.6 M | 28 M | 11.2 M | 1.42 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Arrowhead Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
683 M | 682 M | 102 M | 102 M | 104 M | 106 M | 109 M | 109 M | 111 M | 112 M | 114 M | 115 M | 105 M | 79.9 M | 80.1 M | 79.5 M | 78.8 M | - | 22.7 M | 22.5 M | 23.3 M | 22.9 M | 23.3 M | 19.7 M | 20 M | 20 M | 20 M | 14.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
1.36 B | 1.37 B | 694 M | 694 M | 686 M | 666 M | 864 M | 864 M | 846 M | 448 M | 395 M | 389 M | 373 M | 344 M | 339 M | 373 M | 135 M | - | 112 M | 129 M | 155 M | 103 M | 155 M | 19.7 M | 20 M | 20 M | 20 M | 14.4 M | 8.74 M | 8.74 M | 8.74 M | 34.8 M | 4 M | 4 M | 4 M | 4.3 M | 4.45 M | 4.45 M | 4.45 M | 10.1 M | 7.51 M | 7.51 M | 7.51 M | 6.68 M | 6.75 M | 6.75 M | 6.75 M | 4.93 M | 4.98 M | 4.98 M | 4.98 M | 2.76 M | 2.87 M | 2.87 M | 2.87 M | 1.55 M | 2.39 M | 2.39 M | 2.39 M | 2.25 M | 742 K | 742 K | 742 K |
Deferred Revenue |
94.6 M | 109 M | 112 M | 112 M | 2.4 M | 23 M | - | - | - | - | - | - | 866 K | 16.9 M | 29.8 M | 66.3 M | 74.1 M | - | 97.9 M | 109 M | 111 M | 151 M | 111 M | 6.74 M | 19.3 M | 19.3 M | 19.3 M | 54 M | 77.8 M | 77.8 M | 77.8 M | 125 M | 600 | 943 K | 1.56 M | 1.88 M | 5.27 M | 5.27 M | 5.27 M | 25.6 M | 2.57 M | 2.57 M | 2.57 M | 109 K | 103 K | 103 K | 103 K | 109 K | 103 K | 103 K | 103 K | 109 K | 103 K | 103 K | 103 K | 109 K | 37.5 K | 37.5 K | 37.5 K | 101 K | - | - | - |
Retained Earnings |
-1.92 B | -1.73 B | -1.6 B | -1.6 B | -1.63 B | -1.6 B | -1.8 B | -1.8 B | -1.63 B | -1.45 B | -1.28 B | -1.16 B | -1.03 B | -916 M | -813 M | -862 M | -821 M | - | -663 M | -708 M | -645 M | -581 M | -645 M | -525 M | -504 M | -504 M | -504 M | -422 M | -419 M | -419 M | -419 M | -475 M | -487 M | -487 M | -487 M | -446 M | -433 M | -433 M | -433 M | -411 M | -398 M | -398 M | -398 M | -336 M | -317 M | -317 M | -317 M | -247 M | -225 M | -225 M | -225 M | -177 M | -166 M | -166 M | -166 M | -140 M | -135 M | -135 M | -135 M | -116 M | -114 M | -114 M | -114 M |
Total Assets |
2.11 B | 2.27 B | 1.6 B | 1.6 B | 1.39 B | 1.38 B | 1.01 B | 1.01 B | 1.14 B | 884 M | 955 M | 626 M | 766 M | 796 M | 891 M | 891 M | 692 M | - | 704 M | 639 M | 710 M | 735 M | 710 M | 499 M | 523 M | 523 M | 523 M | 588 M | 350 M | 350 M | 350 M | 341 M | 112 M | 112 M | 112 M | 88.2 M | 104 M | 104 M | 104 M | 144 M | 128 M | 128 M | 128 M | 111 M | 132 M | 132 M | 132 M | 162 M | 183 M | 183 M | 183 M | 92.7 M | 37.3 M | 37.3 M | 37.3 M | 15.2 M | 16.5 M | 16.5 M | 16.5 M | 23.1 M | 15.9 M | 15.9 M | 15.9 M |
Cash and Cash Equivalents |
54.8 M | 189 M | 202 M | 202 M | 227 M | 130 M | 53.9 M | 53.9 M | 103 M | 69.4 M | 128 M | 58.2 M | 111 M | 105 M | 135 M | 202 M | 108 M | - | 86.4 M | 91.6 M | 184 M | 326 M | 184 M | 140 M | 144 M | 144 M | 144 M | 461 M | 222 M | 222 M | 222 M | 190 M | 30.1 M | 30.1 M | 30.1 M | 11.5 M | 24.8 M | 24.8 M | 11.5 M | 102 M | 85.4 M | 85.4 M | 102 M | 62.2 M | 81.2 M | 81.2 M | 62.2 M | 104 M | 133 M | 133 M | 104 M | 59.7 M | 19.1 M | 19.1 M | 59.7 M | 2.93 M | 3.38 M | 3.38 M | 2.93 M | 6.77 M | 7.51 M | 7.51 M | 6.77 M |
Book Value |
2.11 B | 2.27 B | 1.6 B | 1.6 B | 1.39 B | 1.38 B | 1.01 B | 1.01 B | 1.14 B | 884 M | 955 M | 626 M | 766 M | 796 M | 891 M | 891 M | 692 M | - | 704 M | 639 M | 710 M | 735 M | 710 M | 499 M | 523 M | 523 M | 523 M | 588 M | 350 M | 350 M | 350 M | 341 M | 112 M | 112 M | 112 M | 88.2 M | 104 M | 104 M | 104 M | 144 M | 128 M | 128 M | 128 M | 111 M | 132 M | 132 M | 132 M | 162 M | 183 M | 183 M | 183 M | 92.7 M | 37.3 M | 37.3 M | 37.3 M | 15.2 M | 16.5 M | 16.5 M | 16.5 M | 23.1 M | 15.9 M | 15.9 M | 15.9 M |
Total Shareholders Equity |
466 M | 614 M | 568 M | 568 M | 466 M | 522 M | 52.6 M | 56.1 M | 185 M | 339 M | 484 M | 174 M | 271 M | 382 M | 465 M | 396 M | 399 M | 474 M | 452 M | 373 M | 409 M | 437 M | 373 M | 454 M | 462 M | 493 M | 494 M | 500 M | 245 M | 245 M | 245 M | 172 M | 95.8 M | 95.8 M | 95.8 M | 70.8 M | 81.4 M | 81.4 M | 81.4 M | 97.8 M | 95.6 M | 95.6 M | 95.6 M | 92.9 M | 110 M | 110 M | 110 M | 146 M | 167 M | 167 M | 167 M | 82.7 M | 27.5 M | 27.5 M | 27.5 M | 8.97 M | 10 M | 10 M | 10 M | 16.2 M | 12.8 M | 12.8 M | 12.8 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Arrowhead Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
USA
Russia
Niderland
France
Israel
Australia
Danmark
